Table 1.
Bio-clinical and molecular characteristics of GnPT according to the presence or the absence of gonadotropin immunostaining
| FSH/LH | SF1 | P | |
|---|---|---|---|
| I. Clinicopathological data | |||
| Number of patients | 41 | 13 | |
| Gender | 30 M; 11 F | 7 M; 6 F | ns |
| Age (years) | 58 (36–83) | 67 (41–76) | 0.040 |
| Tumor size [cm] | 3.20 [1.40–5.30] | 3.00 [2.00–4.50] | ns |
| Giant (%) | 9/40 (22.5%) | 3/13 (23.1%) | ns |
| Invasive tumors | 25/40 (62.5%) | 7/13 (53.8%) | ns |
| Recurrent | 4/41 (9.8%) | 3/13 (23.1%) | ns |
| Ki67 (%) | 2.50 (0.10–6.20) | 2.30 (0.20–8.0) | ns |
| II. Gene expression | |||
| SF1/βactin mRNA | 19.1 [0.13–492.0] | 21.4 [2.02–179] | ns |
| βFSH/βactin mRNA | 66.9 [0.43–1067] | 19.2 [0.61–680] | 0.042 |
| βLH/βactin mRNA | 35.0 [0.23–4820] | 9.74 [0.02–351] | ns |
| CCND1/βactin mRNA | 16.0 [1.18–98.1] | 18.2 [1.94–115] | ns |
| CCNA2/βactin mRNA | 0.07 [0.01–1.27] | 0.08 [0.01–1.81] | ns |
| CCNB1/βactin mRNA | 0.57 [0.05–2.75] | 0.70 [0.11–1.78] | ns |
| Caspase 3/βactin mRNA | 0.32 [0.01–1.36] | 0.15 [0.01–1.98] | ns |
| AIP/βactin mRNA | 6.80 [0.29–33.9] | 3.25 [1.03–7.27] | 0.024 |
| D2R/βactin mRNA | 7.71 [0.08–213] | 3.85 [0.44–49.2] | ns |
| III. Immunohistochemistry | |||
| D2R mAba | 1/11 (9.0%) | 1/4 (25.0%) | ns |
| D2R pAba | 9/13 (69.2%) | 1/2 (50.0%) | ns |
| AIPa | 25/34 (73.5%) | 4/6 (66.7%) | ns |
| AIP score | 3 [1–6] | 3 [1–4] | ns |
aPositive immunostaining